血管内治疗后高血压和静脉复缩之间的相关性:基于随机试验衍生的队列的元分析
Cheng Zhang1,2, Yarong Ma3, Qi Zhang4
1Department of General Surgery (Vascular Surgery), the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
BMC cardiovascular disorders
|December 30, 2025
概括
根据这次元分析,高血压不会显著影响支架后的初级静止. 由于研究的局限性和适度的证据确定性,需要进一步的研究.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 临床研究 临床研究
背景情况:
- 高血压是动脉样硬化和动脉狭窄的已知危险因素.
- 血管内治疗后高血压和静脉复缩之间的关联尚不清楚.
研究的目的:
- 通过对随机试验的元分析,研究在内血管治疗后高血压和静止症之间的关系.
- 为了确定高血压是否影响支架后初级静止病的发生率.
主要方法:
- 对1990年1月至2024年1月期间发表的随机试验进行了PubMed,EMBASE和Cochrane图书馆数据库的系统搜索.
- 来自6项随机对照试验的数据,涉及5142名参与者,使用相对风险 (RR) 和95%置信区间进行了分析.
- STATA 16.0用于聚合效应分析,子组分析和元回归.
主要成果:
- 在分析中,没有发现高血压和支架后的初级缩之间具有统计学意义的关系 (RR = 1.05,95% CI: 0.86-1.27,P = 0.66).
- 根据抗血小板持续时间,器械类型和血管床的亚组分析显示出一致的结果.
结论:
- 高血压似乎不会显著影响内血管治疗后的初级静止率.
- 证据的确定性是中等的,并且由于潜在的残留混和研究局限性,研究结果应谨慎解释.
- 进一步的强有力的预后研究是有必要的,以澄清高血压在静止病中的作用.
相关概念视频
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
437
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
437
01:29Hypertension II: Pathophysiology
700
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
700
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
418
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
418
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
874
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
874
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
564
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
564
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
435
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
435